Sling Therapeutics Raises 123M for Drug Trial
Sling Therapeutics has raised 123 million dollars in funding to advance a late-stage trial of its oral drug for thyroid eye disease. The financing will support testing linsitinib as a potential alternative to current intravenous treatments.
Xurve View
Insights:
Xurve View
Sling Therapeutics secured $123M in Series C financing on Wednesday morning to advance late-stage trials of its experimental oral therapy for thyroid eye disease. The privately held developer aims to evaluate linsitinib in roughly 130 adults diagnosed with moderate-to-severe active disease. If cleared, the candidate would become the first oral option in a market dominated by intravenous infusions.
